Secura Bio's executive team is an insider investor group tied to Secura Bio, a Berkeley Heights, New Jersey commercial-stage oncology company established in 2019. The group has participated as an equity backer of Secura Bio rather than operating as a conventional venture fund. Its relevant investment context is U.S. biotechnology, oncology, pharmaceuticals and life sciences, making it a niche strategic/insider capital source for company-specific healthcare financing.